CURRENT RECRUITING TRIALS

WN39434
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, And Safety Study Of Balovaptan In Adults With Autism Spectrum Disorder With A 2-Year Open-Label Extension

From clinicaltrials.gov:

This study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults (18 years and older) with autism spectrum disorder (ASD).

More information

PATIENTS: For information on Autism Spectrum Disorder clinical trials, please contact info-CRU.neuro@mcgill.ca.

UPCOMING TRIALS

to come